FDA record · warning letter

FDA warning letter: www.semaspace.com (Oct 2, 2023)

On Oct 2, 2023, FDA issued a warning letter to www.semaspace.com under the subject "Finished Pharmaceuticals/Unapproved New Drug/Misbranded". It names semaglutide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to www.semaspace.com
Field	What FDA’s record states	Source
Recipient	www.semaspace.com	FDA letter
Location	Not published by FDA	n/a
Letter date	Oct 2, 2023	FDA letter
Posted by FDA	Oct 10, 2023	FDA index
Issuing office	Center for Drug Evaluation and Research \| CDER	FDA letter
Subject	Finished Pharmaceuticals/Unapproved New Drug/Misbranded	FDA letter
MARCS-CMS number	665848	FDA letter
GLP-1 drugs named	Semaglutide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“As discussed below, FDA has observed that www.semaspace.com introduces into interstate commerce unapproved and misbranded semaglutide drug products. There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs.”FDA warning letter to www.semaspace.com, Oct 2, 2023 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters